Cytokinetics (CYTK) PT Raised to $48 at JMP Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices steady as investors weigh US-Iran war escalation
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Pentagon reportedly locked down, hazmat teams responding
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Cytokinetics and JI XING Announce Expansion of Collaboration to Include Licensing of Omecamtiv Mecarbil in China; RTW to Add to Its Investment in Cytokinetics
December 20, 2021 7:30 AM ESTJI XING to Develop and CommercializeNovel Cardiac Myosin Activator in Patients with Heart Failure
Cytokinetics to Receive $70 Million in Committed Capital;Up to an Additional $330 Million in Potential Milestone Payments Plus Royalties
Cytokinetics to Host Conference Call and Webcast Today at 8:30 am Eastern Time
SOUTH SAN FRANCISCO, Calif., and SHANGHAI, China, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Ji Xing Pharmaceuticals Limited (JI XING), a biopharmaceutical company based in Shanghai and backed by RTW... More
